乌拉地尔联合贝那普利治疗冠心病合并心力衰竭患者的价值  

Value of urapidil combined with benazepril on patients with coronary heart disease and heart failure

作　　者：张娜[1] 朱红利 李雪青[3] 崔艳敏 宫阳阳 刘倩[1] 宋岳涵 ZHANG Na;ZHU Hongli;LI Xueqing;CUI Yanmin;GONG Yangyang;LIU Qian;SONG Yuehan(Department of General Medicine,the No.2 Hospital of Baoding,Baoding,Hebei,China,071000;Department of Geriatrics,the No.2 Hospital of Baoding,Baoding,Hebei,China,071000;Department of Infectious Diseases,the No.2 Hospital of Baoding,Baoding,Hebei,China,071000)

机构地区：[1]保定市第二医院全科医学科,河北保定071000 [2]保定市第二医院老年病科,河北保定071000 [3]保定市第二医院感染性疾病科,河北保定071000

出　　处：《分子诊断与治疗杂志》2024年第6期1024-1027,共4页Journal of Molecular Diagnostics and Therapy

基　　金：保定市社发类项目(2141ZF010)。

摘　　要：目的 探究乌拉地尔联合贝那普利治疗冠心病合并心力衰竭患者的价值。方法 研究2020年11月至2023年11月收治的118例冠心病合并心力衰竭患者,采用随机数字表法将上述患者分为观察组(n=59,采用乌拉地尔联合贝那普利治疗)和对照组(n=59,单独采用贝那普利治疗),治疗一个月后比较两组患者疗效、心功能、NT-proBNP水平差异、运动耐力及不良反应发生情况。结果 观察组总有效率相较于对照组更高,差异有统计学意义(χ^(2)=4.827, P<0.05);相较于治疗前,治疗后两组患者左心室射血分数(LVEF)、每分钟搏出量(SV)均有上升,且观察组相较于对照组均更高,差异有统计学意义(t=2.345、3.198, P<0.05);相较于治疗前,治疗后两组患者左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)均有下降,且观察组相较于对照组均更低,差异有统计学意义(t=2.265、2.007, P<0.05);相较于治疗前,治疗后两组患者6分钟步行距离(6MWT)均有上升,且观察组相较于对照组均更高,差异有统计学意义(t=2.018, P<0.05);相较于治疗前,治疗后两组患者NT-proBNP水平均有下降,且观察组相较于对照组均更低,差异有统计学意义(t=3.575, P<0.05);比较两组患者不良反应总发生率无统计意义(P>0.05)。结论 乌拉地尔联合贝那普利治疗在冠心病合并心力衰竭患者中具有较高应用应用价值。Objective To explore the value of urapidil combined with benazepril on patients with coronary heart disease complicated with heart failure.Methods A total of 118 patients with coronary heart dis-ease and heart failure who were admitted from November 2020 to November 2023 were studied.They were ran-domly divided into an observation group(n=59,treated with urapidil combined with benazepril)and a control group(n=59,treated with benazepril alone)using random number table method.After one month of treatment,the efficacy,cardiac function,NT-proBNP levels,exercise tolerance,and occurrence of adverse reactions were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group(χ^(2)=4.827,P<0.05).Compared with before treatment,the left ventricular ejection frac-tion(LVEF)and stroke volume(SV)in both groups increased after treatment,with the observation group showing higher LVEF and SV(t=2.345,3.198,P<0.05).The left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)decreased in both groups after treatment compared to before treatment,and the LVEDD and LVESD in the observation group were lower(t=2.265,2.007,P<0.05).Com-pared with before treatment,the 6-minute walking distance(6MWT)increased after treatment in both groups,and the 6MWT was higher in the observation group(t=2.018,P<0.05).The level of NT-proBNP in both groups after treatment decreased compared with before treatment,with the NT-proBNP in the observation group being lower(t=3.575,P<0.05).There was no statistical significance in the total incidence rate of adverse reac-tions between the groups(P>0.05).Conclusion Urapidil combined with benazepril has a high application value for patients with coronary heart disease complicated by heart failure.

关 键 词：乌拉地尔 贝那普利 冠心病 心力衰竭 氨基末端脑利钠肽前体 

分 类 号：R541.4[医药卫生—心血管疾病] R541.6[医药卫生—内科学]